Cargando…
Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer
BACKGROUND: Curcumin (Cur), a bioactive component of Chinese traditional medicine, has demonstrated inhibitory properties against cancer cell proliferation while synergistically enhancing the anticancer efficacy of erlotinib (Er). However, the individual limitations of both drugs, including poor aqu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505307/ https://www.ncbi.nlm.nih.gov/pubmed/37717020 http://dx.doi.org/10.1186/s12951-023-02099-4 |
_version_ | 1785106890213031936 |
---|---|
author | Chen, Zhihuai Wei, Xinqi Zheng, Yunru Zhang, Zongwei Gu, Wang Liao, Wenjun Zhang, Hua Wang, Xiaoying Liu, Jian Li, Hua Xu, Wei |
author_facet | Chen, Zhihuai Wei, Xinqi Zheng, Yunru Zhang, Zongwei Gu, Wang Liao, Wenjun Zhang, Hua Wang, Xiaoying Liu, Jian Li, Hua Xu, Wei |
author_sort | Chen, Zhihuai |
collection | PubMed |
description | BACKGROUND: Curcumin (Cur), a bioactive component of Chinese traditional medicine, has demonstrated inhibitory properties against cancer cell proliferation while synergistically enhancing the anticancer efficacy of erlotinib (Er). However, the individual limitations of both drugs, including poor aqueous solubility, lack of targeting ability, short half-life, etc., and their distinct pharmacokinetic profiles mitigate or eliminate their combined antitumor potential. RESULTS: In this study, we developed a molybdenum disulfide (MoS(2))-based delivery system, functionalized with polyethylene glycol (PEG) and biotin, and co-loaded with Cur and Er, to achieve efficient cancer therapy. The MoS(2)-PEG-Biotin-Cur/Er system effectively converted near-infrared (NIR) light into heat, thereby inducing direct photothermal ablation of cancer cells and promoting controlled release of Cur and Er. Biotin-mediated tumor targeting facilitated the selective accumulation of MoS(2)-PEG-Biotin-Cur/Er at the tumor site, thus enhancing the synergistic antitumor effects of Cur and Er. Remarkably, MoS(2)-PEG-Biotin-Cur/Er achieved the combination of synergistic chemotherapy and photothermal therapy (PTT) upon NIR irradiation, effectively suppressing lung cancer cell proliferation and inhabiting tumor growth in vivo. CONCLUSIONS: The as-synthesized MoS(2)-PEG-Biotin-Cur/Er, featuring high targeting ability, NIR light-responsive drug release, and the integration of synergistic chemotherapy and PTT, may provide a promising strategy for the treatment of lung cancer in clinical practice. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-02099-4. |
format | Online Article Text |
id | pubmed-10505307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105053072023-09-18 Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer Chen, Zhihuai Wei, Xinqi Zheng, Yunru Zhang, Zongwei Gu, Wang Liao, Wenjun Zhang, Hua Wang, Xiaoying Liu, Jian Li, Hua Xu, Wei J Nanobiotechnology Research BACKGROUND: Curcumin (Cur), a bioactive component of Chinese traditional medicine, has demonstrated inhibitory properties against cancer cell proliferation while synergistically enhancing the anticancer efficacy of erlotinib (Er). However, the individual limitations of both drugs, including poor aqueous solubility, lack of targeting ability, short half-life, etc., and their distinct pharmacokinetic profiles mitigate or eliminate their combined antitumor potential. RESULTS: In this study, we developed a molybdenum disulfide (MoS(2))-based delivery system, functionalized with polyethylene glycol (PEG) and biotin, and co-loaded with Cur and Er, to achieve efficient cancer therapy. The MoS(2)-PEG-Biotin-Cur/Er system effectively converted near-infrared (NIR) light into heat, thereby inducing direct photothermal ablation of cancer cells and promoting controlled release of Cur and Er. Biotin-mediated tumor targeting facilitated the selective accumulation of MoS(2)-PEG-Biotin-Cur/Er at the tumor site, thus enhancing the synergistic antitumor effects of Cur and Er. Remarkably, MoS(2)-PEG-Biotin-Cur/Er achieved the combination of synergistic chemotherapy and photothermal therapy (PTT) upon NIR irradiation, effectively suppressing lung cancer cell proliferation and inhabiting tumor growth in vivo. CONCLUSIONS: The as-synthesized MoS(2)-PEG-Biotin-Cur/Er, featuring high targeting ability, NIR light-responsive drug release, and the integration of synergistic chemotherapy and PTT, may provide a promising strategy for the treatment of lung cancer in clinical practice. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-02099-4. BioMed Central 2023-09-16 /pmc/articles/PMC10505307/ /pubmed/37717020 http://dx.doi.org/10.1186/s12951-023-02099-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chen, Zhihuai Wei, Xinqi Zheng, Yunru Zhang, Zongwei Gu, Wang Liao, Wenjun Zhang, Hua Wang, Xiaoying Liu, Jian Li, Hua Xu, Wei Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
title | Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
title_full | Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
title_fullStr | Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
title_full_unstemmed | Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
title_short | Targeted co-delivery of curcumin and erlotinib by MoS(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
title_sort | targeted co-delivery of curcumin and erlotinib by mos(2) nanosheets for the combination of synergetic chemotherapy and photothermal therapy of lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505307/ https://www.ncbi.nlm.nih.gov/pubmed/37717020 http://dx.doi.org/10.1186/s12951-023-02099-4 |
work_keys_str_mv | AT chenzhihuai targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT weixinqi targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT zhengyunru targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT zhangzongwei targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT guwang targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT liaowenjun targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT zhanghua targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT wangxiaoying targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT liujian targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT lihua targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer AT xuwei targetedcodeliveryofcurcuminanderlotinibbymos2nanosheetsforthecombinationofsynergeticchemotherapyandphotothermaltherapyoflungcancer |